Vol. 1 No. 8 (2021)
Reimbursement Reviews

Dinutuximab (Unituxin)

Published August 13, 2021

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses dinutuximab (Unituxin) 17.5 mg/m2 per day, administered as an IV infusion over 10 hours to 20 hours for 4 consecutive days per treatment cycle.
  • Indication: For the treatment of high-risk neuroblastoma patients in their first relapse or determination of refractory disease in combination with irinotecan, temozolomide, and granulocyte-macrophage colony-stimulating factor.